Disease Overview：Diffuse Large B-Cell Lymphoma（DLBCL）
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by aggressive proliferation of mature B-lymphocytes. It typically presents with rapidly enlarging lymphadenopathy, systemic “B symptoms” (fever, night sweats, weight loss), and extranodal involvement in sites such as the gastrointestinal tract, bone marrow, or central nervous system. Diagnosis relies on histopathology, immunohistochemistry (CD20+, CD79a+, PAX5+), and molecular profiling—including cell-of-origin classification (GCB vs. ABC subtypes) and detection of high-risk genetic alterations (e.g., MYC/BCL2 double-hit status). First-line therapy remains R-CHOP immunochemotherapy; however, approximately 30–40% of patients experience refractory disease or relapse, necessitating salvage regimens, autologous stem cell transplantation, or novel agents such as polatuzumab vedotin, tafasitamab, or CAR-T cell therapies (e.g., axicabtagene ciloleucel). Prognosis varies significantly based on IPI score, molecular features, and treatment response—highlighting the need for precision oncology approaches.
China offers compelling advantages for DLBCL management: leading academic centers—including Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—maintain internationally accredited hematologic oncology programs with deep expertise in risk-stratified protocols and cellular therapy. State-of-the-art infrastructure includes next-generation sequencing platforms, digital pathology integration, and FDA/EMA-approved CAR-T manufacturing facilities operating under stringent GMP standards. Clinical outcomes align closely with Western benchmarks: five-year progression-free survival exceeds 65% in standard-risk cohorts, while real-world data from multicenter registries demonstrate comparable efficacy and safety for bispecific antibodies and CD19-directed CAR-T in relapsed/refractory settings. Crucially, treatment costs remain substantially lower—R-CHOP cycles cost approximately 30–50% less than in the U.S. or EU, and CAR-T therapy is priced at roughly 40% of Western equivalents—without compromising quality or regulatory oversight.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients. Our services include verified hospital referrals, pre-treatment eligibility assessment, transparent itemized pricing in USD/EUR, visa support, multilingual clinical coordination, accommodation logistics, and post-discharge follow-up—all coordinated by oncology-specialized case managers. We prioritize evidence-based care pathways and uphold strict confidentiality and ethical standards throughout the patient journey.
Diffuse Large B-Cell Lymphoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Diffuse Large B-Cell Lymphoma (DLBCL)
Non-Surgical/Medical Therapies
*Target Criteria*: Newly diagnosed, fit patients (ECOG 0–2), no CNS involvement; relapsed/refractory cases after prior chemoimmunotherapy.
- •R-CHOP Regimen (Standard First-Line)
- Cyclophosphamide (750 mg/m² IV): $110–$140 per dose - Doxorubicin (50 mg/m² IV): $190–$230 per dose - Vincristine (1 $85–$110 per dose - Prednisone (100 mg $8–$12 per cycle - *Supportive Care*: G-CSF (filgrastim, 300 µg SC): $140–$180 per injection (as needed); antiemetics, hydration, monitoring
- •Diagnostic & Monitoring Labs/Exams (Per, LFTs, renal panel, LDH, β2-microglobulin: $45–$65
- Bone marrow biopsy (diagnostic):
$290–$360 - Flow cytometry + IHC on tissue: $220–$280Surgical/Procedural/Interventional Options
*Eligibility*: Confirmed diagnosis requiring tissue confirmationlumbar puncture); complications (bowel obstruction, massive adenopathy).
- •
- Pre-op workup (CBC, coagulation, ECG, chest X-ray):
$130–$170- •
- Debulking surgery (rare, only for life-threatening GI obstruction or airway compromise):
$$3,400 (including anesthesia, OR time, pathology) - Pre-op workup (enhanced CT/MRI): $420–$590Special/Complex Condition Management
- •
- Bridging chemo + lymphodepletion (fludarabine/cyclophosphamide): $1,9400 - Inpatient monitoring (28-day minimum): $4,200–$6,100
- •CNS Involvement: High-dose methotrexate (IV) + cytarabine + intrathecal therapy — 4–6 cycles: $7,300–$9,600
Quick Selection Guide
- •Fit <65 years, standard-risk: R-CHOP ($12,400–$15,800 total)
- •Age ≥75 or significant comorbidities (e.g., severe CAD, CKD): R-miniCHOP or R-GemOx — lower toxicity, $7,200–$9,500
- •Budget-constrained (<$5,000): Generic rituximab + CHOP (non-biosimilar doxorubicin — $4,100–$5,300, with reduced supportive care
- •Relapsed/refractory with adequate organ function: CAR-T preferred if accessible; otherwise, polatuzumab + bendamustine + rituximab ($8,900–$11,300)
- •CNS-positive or bulky disease (>10 cm): Immediate high-dose systemic + intrathecal therapy — $10,600–$13,900
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Diffuse Large B-Cell Lymphoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Diffuse Large B-Cell Lymphoma treatment with China top medical destinations:
